Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a stronger blood thinner save trauma patients from deadly clots?

NCT ID NCT07506473

Prevention Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a higher dose of the blood thinner enoxaparin can better prevent dangerous blood clots in the legs or lungs of severely injured patients. About 540 adults in intensive care after trauma will receive either the standard or a double dose. The goal is to see if the higher dose reduces clots without increasing serious bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 540 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All adult patients (age ≥18 years) admitted to an intensive care unit following trauma with an expected stay \>48 hours and a planned administration of LMWH. * Affiliation to the French social security system or European (CEAM) Exclusion Criteria: * Prehospital cardiac arrest * Hospital admission \>72 hours * More than one dose of prophylactic anticoagulant already administered since trauma * Renal failure defined by creatinine clearance of 30 mL/min or less (Cockcroft-Gault formula) * Body weight \>100 kg or \<45 kg * Indication for therapeutic anticoagulation * Major known thrombophilia (e.g. antiphospholipid syndrome, antithrombin deficiency) * Constitutional bleeding disorder (haemophilia, von Willebrand disease, coagulation factor deficiency, platelet disorder). * Thrombocytopenia inferior to 50 G.L-1 * History of heparin-induced thrombocytopenia * Study drug hypersensitivity * Limitation of life support, life expectancy ≤7 days or palliative care * Contraindication to the administration of anticoagulant according to the SPC (Active clinically significant bleeding or a condition associated with a high risk of bleeding, such as a recent haemorrhagic stroke, gastrointestinal ulcer, the presence of a malignant tumour at high risk of bleeding, recent brain, spinal or ophthalmological surgery, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intrarachid or intracerebral vascular anomalies.) * pregnant or breastfeeding woman * Inclusion in another experimental trial * Protected person (art. L1121-5 to L1121-8 of the CSP or art. 31 to 35 of European regulation 536/2014)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe trauma patient are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

injury venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe trauma patient Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP Bicêtre

    Le Kremlin-Bicêtre, 94270, France

  • Assistance Publique - Hôpitaux de Marseille

    Marseille, 13005, France

  • CHRU Lille

    Lille, 59000, France

  • CHU Angers

    Angers, 49100, France

  • CHU Clermont Ferrand

    Clermont-Ferrand, 63000, France

  • CHU Grenoble Alpes

    Grenoble, 38000, France

  • CHU Montpellier

    Montpellier, 34080, France

  • CHU Nantes

    Nantes, 44000, France

  • CHU Rennes

    Rennes, 35000, France

  • CHU Strasbourg

    Strasbourg, 67200, France

  • CHU Tours

    Tours, 37000, France

  • CHU de Toulouse

    Toulouse, 31300, France

  • HCL Lyon Sud

    Lyon, 69310, France

  • Hôpital Beaujon AP-HP

    Clichy, 92110, France

  • Hôpital Edouard Herriot HCL

    Lyon, 69003, France

  • Hôpital Européen Georges Pompidou AP-HP

    Paris, 75015, France

  • Hôpital Pitié-Salpêtrière APHP

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.